Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AltaRex and Dompe establish OvaRex alliance for Europe

Nov. 28, 2000

Schering and MediGene begin HPV vaccine trial

Nov. 23, 2000

European Commission grants orphan drug status to Mylotarg for treatment of AML

Nov. 16, 2000

Potential cellular mechanism for adverse cardiac effects of Herceptin described at AHA sessions

Nov. 16, 2000

Independent safety board recommends continuation of Theratope vaccine phase III trial

Nov. 15, 2000

York Medical acquires Norelin from Biostar

Nov. 14, 2000

Data presented at Heat Shock Proteins symposium support clinical application of HspE7

Nov. 10, 2000

First phase III trial of HspE7 commences in anal dysplasia

Nov. 9, 2000

Update on worldwide phase III trials of Maxamine

Nov. 9, 2000

Maxamine protects against IL-2 toxicity in murine model

Nov. 8, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...